Compounders prescribing GLP-1s put pricing pressure on Novo, Lilly
Hims won — for now.
Since 2022, telehealth companies and compounding pharmacies have brought a new type of competition for drugmakers. Pharma giants, long protected by patents and market exclusivity, suddenly found themselves undercut on price …
Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Compounded forms of the molecule behind Eli Lilly’s metabolic blockbusters Mounjaro and Zepbound that have vitamin B12 added to them may be unsafe, Lilly said Thursday.
Lilly and its fellow GLP-1-based drugmaker Novo Nordisk have …
Switching GLP-1 Medications Is Common, Can Help People Stick With Weight-Loss Treatment
THURSDAY, March 12, 2026 — People frequently switch between different weight-loss drugs, swapping Ozempic for Zepbound and vice versa within the first year of treatment, a new study reports.What’s more, those patients who do swap GLP-1 drugs are mor…
STAT+: The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them?
The FDA is targeting telehealth marketing of GLP-1 drugs. But those companies may not be the only ones under the microscope.
Ozempic-maker Novo Nordisk struggles as GLP-1 drugs continue to dominate medicine, culture
The FDA criticized the maker of Ozempic and Wegovy, Novo Nordisk, for “serious violations” related to the reporting of possible side effects linked to semaglutide, the active ingredient in the drug. NBC News’ Emily Lorsch reports on the GLP-1 drugs.
FDA Warns GLP-1 Maker Over Failure to Properly Report Deaths, Strokes
(MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…
GLP-1 Drugs May Benefit Cancer Patients With Brain Lesions
(MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients…
Wegovy May Have Higher Risk of ‘Eye Stroke,’ Vision Loss Than Ozempic
Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images
A new study has found that the GLP-1 drug Wegovy is linked with a higher risk of “eye stroke,” especially in men.
Q&A: How small steps can help GLP-1 users build healthier habits
A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It’s a simple premise: What if something as small as a digital nudge could put someone on the path to healthier habits while taking GLP-1 medications?
GLP-1 Receptor Agonists Similarly Effective Across Age, Race, Starting Weight
WEDNESDAY, March 11, 2026 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss appear to be similarly effective among adults across ages, races, and starting weights, according to a review published online March 2 in JAMA…